Atai Life Sciences (NASDAQ: ATAI) reported its second quarter 2023 financial results and provided corporate updates. At this time Atai has no revenue to...
Atai noted it was exploring strategic options for the study. The post Atai May Step Away from Ketamine Study After Releasing Positive Results appeared...
The release of quarterly financial reports over the past few weeks is providing some much-needed insight into the state of the industry. It is becoming...
Source: Clive Maund 08/04/2023 Technical Analyst Clive Maund reviews Awakn Life Sciences Corp.'s 26-month and year-to-date charts to tell you...
Welcome to Startups Weekly. Sign up here to get it in your inbox every Friday morning. State-sponsored bad actors have long been able to make “deepfake”...
On Monday, publicly-traded psychedelic company Cybin announced an overnight public offering, and its stock paid the price. This came as no surprise to...
Several US states have psychedelic-favored legislation underway, but none more than California. The state is pioneering psychedelic reform with two major...
This story was reprinted with permission from Crain New York and written by Amanda D’Ambrosio. Last month, federal regulators released research guidance...
Kentucky has made psychedelic history, but will it continue to do so? At the beginning of June, the state announced that it may allocate $42 million...
FSD Pharma successfully countered a $4 million claim, but still had to cough up nearly half of that. The post FSD Pharma Wins Multi-Million Dollar Dispute...